Stock ALCJ CROSSJECT
Add to a list
To use this feature you must be a member
Log inSign up

Crossject Stock

Equities

ALCJ

FR0011716265

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris
Other stock markets
 07:17:59 2024-04-24 am EDT 		5-day change 1st Jan Change
2.13 EUR 0.00% Intraday chart for Crossject +2.65% -57.14%
Apr. 03 CROSSJECT : Patience is a virtue… hopefully AL
Apr. 02 Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2023 12.83M 13.71M Sales 2024 * 3.7M 3.96M Capitalization 80.99M 86.61M
Net income 2023 -8M -8.55M Net income 2024 * -15M -16.04M EV / Sales 2023 14.7 x
Net Debt 2023 * 25.8M 27.59M Net Debt 2024 * 27.8M 29.73M EV / Sales 2024 * 29.4 x
P/E ratio 2023 *
-3.74 x
P/E ratio 2024 *
-5.33 x
Employees 110
Yield 2023 *
-
Yield 2024 *
-
Free-Float 61.18%
More Fundamentals * Assessed data

Chart Crossject

Dynamic Chart

Latest news about Crossject

CROSSJECT : Patience is a virtue… hopefully AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CROSSJECT : Invest Securities slightly reduces its target CF
CROSSJECT : Securing the financing needs AL
Crossject: share price falls after convertible bond issue CF
Crossject Société Anonyme announced that it expects to receive ?12 million in funding CI
CROSSJECT : No news is not always good news... AL
Crossject: strategy advances, but visibility worries CF
CROSSJECT : Marketing initiative in the US AL
Crossject: Syneos Health hired for Zepizure in the USA CF
French Pharmaceutical Crossject Taps Syneos Health for US Commercialization of Epilepsy Rescue Treatment MT
CROSSJECT : A new distribution agreement in Northern Europe AL
France's Crossject Inks New Commercialization Deal for Epileptic Seizure Therapy in Northern EU MT
Crossject: commercial agreement in Northern Europe CF
Crossject Signs ZENEO(R) Commercialization Agreement for Northern Europe CI
More news

Analyst Recommendations on Crossject

CROSSJECT : Patience is a virtue… hopefully AL
CROSSJECT : Invest Securities slightly reduces its target CF
CROSSJECT : Securing the financing needs AL
CROSSJECT : No news is not always good news... AL
CROSSJECT : Marketing initiative in the US AL
More recommendations

Press releases Crossject

Crossject trading on Euronext to resume as usual on Wednesday April 3 GL
Crossject advances in its U.S. Strategy and reports Financial Results for 2023 GL
Crossject gender equality score reaches 96/100 in 2024 GL
Crossject gender equality score reaches 96/100 in 2024 AQ
Crossject obtains a financing up to €12 million, in two tranches GL
More press releases

News in other languages on Crossject

Bolsa de Madrid: Después de Semana Santa, algo va mal
CROSSJECT : La patience est une vertu... espérons-le
Après Pâques, un truc qui cloche
En Direct des Marchés : Thales, Renault, Eurofins, Virbac, Atos, Clariant, Sika, Genmab...
La cotation sur l’action de Crossject à Euronext reprendra comme d’habitude le mercredi 3 avril
More news

Quotes and Performance

1 day-3.52%
1 week-0.96%
Current month-34.76%
1 month-38.47%
3 months-60.63%
6 months-47.58%
Current year-58.65%
More quotes

Highs and lows

1 week
1.97
Extreme 1.97
2.22
1 month
1.83
Extreme 1.828
3.47
Current year
1.83
Extreme 1.828
5.96
1 year
1.83
Extreme 1.828
5.96
3 years
1.41
Extreme 1.408
5.96
5 years
1.04
Extreme 1.04
5.96
10 years
1.02
Extreme 1.02
11.25
More quotes

Managers and Directors - Crossject

Managers TitleAgeSince
Patrick Alexandre CEO
 Chief Executive Officer 61 01-08-07
Olivier Giré PRN
 Corporate Officer/Principal - 15-12-31
Isabelle Liebschütz PRN
 Corporate Officer/Principal - 12-12-31
Members of the board TitleAgeSince
Daniel Teper BRD
 Director/Board Member 64 23-06-06
Eric Nemeth BRD
 Director/Board Member 65 -
Philippe Monnot CHM
 Chairman 65 -
More insiders

Quotes

Date Price Change Volume
24-04-24 2.13 0.00% 8 423
24-04-23 2.13 -0.93% 26,766
24-04-22 2.15 +4.37% 36,418
24-04-19 2.06 +0.98% 48,317
24-04-18 2.04 -1.69% 46,456

Real-time Euronext Paris, April 24, 2024 at 03:12 am EDT

More quotes

Company Profile

Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Sector
Medical Equipment, Supplies & Distribution
More about the company

Income Statement Evolution

More financial data

Ratings for Crossject

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.13 EUR
Average target price
5 EUR
Spread / Average Target
+134.74%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ALCJ Stock